Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: A pilot, prospective study
Bobby Kwanghoon Han, Igor Kuzin, John P. Gaughan, Nancy J. Olsen, Andrea Bottaro
Dive into the research topics of 'Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: A pilot, prospective study'. Together they form a unique fingerprint.